Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Earnings for Ovid Therapeutics Inc. (OVID)
Earnings in 2023 (TTM): $-52,338,959
According to Ovid Therapeutics Inc.'s latest financial reports the company's current earnings (TTM) are $-52,338,959. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Ovid Therapeutics Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-52,338,959 | $-52,338,959 |
| 2022 | $-54,169,029 | $-51,408,292 |
| 2021 | $124.16 M | $122.83 M |
| 2020 | $-81,035,576 | $-80,728,728 |
| 2019 | $-60,461,243 | $-59,258,017 |
| 2018 | $-51,979,610 | $-51,979,610 |
| 2017 | $-64,806,054 | $-64,806,054 |
| 2016 | $-22,414,352 | $-22,414,352 |
| 2015 | $-13,160,093 | $-13,160,093 |
| 2014 | $-446,892 | $-446,892 |